We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

288 hedge funds and large institutions have $5.34B invested in Intra-Cellular Therapies Inc. in 2023 Q2 according to their latest regulatory filings, with 51 funds opening new positions, 115 increasing their positions, 78 reducing their positions, and 36 closing their positions.

New
Increased
Maintained
Reduced
Closed

55% more call options, than puts

Call options by funds: $16.6M | Put options by funds: $10.7M

47% more repeat investments, than reductions

Existing positions increased: 115 | Existing positions reduced: 78

42% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 36

38% more funds holding in top 10

Funds holding in top 10: 8 → 11 (+3)

18% more capital invested

Capital invested by funds: $4.55B → $5.34B (+$797M)

5% more funds holding

Funds holding: 274 → 288 (+14)

Holders
288
Holders Change
+14
Holders Change %
+5.11%
% of All Funds
4.52%
Holding in Top 10
11
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+37.5%
% of All Funds
0.17%
New
51
Increased
115
Reduced
78
Closed
36
Calls
$16.6M
Puts
$10.7M
Net Calls
+$5.94M
Net Calls Change
-$34M

Top Buyers

1
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$36.7M
2
Holocene Advisors
Holocene Advisors
New York
+$36.1M
3
Macquarie Group
Macquarie Group
Australia
+$35.4M
4
NIP
Nicholas Investment Partners
California
+$31.1M
5
PAMS
Pictet Asset Management (Switzerland)
Switzerland
+$30.5M

Top Sellers

1
Wellington Management Group
Wellington Management Group
Massachusetts
-$207M
2
WA
Wasatch Advisors
Utah
-$62M
3
Fidelity Investments
Fidelity Investments
Massachusetts
-$47.1M
4
DM
Deerfield Management
New York
-$39.7M
5
Citadel Advisors
Citadel Advisors
Florida
-$36.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
PCIA
151
Prime Capital Investment Advisors
Kansas
$1.44M +$467K +7,500 +49%
AR
152
Advisory Research
Illinois
$1.39M +$1.09M +17,515 +398%
First Trust Advisors
153
First Trust Advisors
Illinois
$1.39M -$1.78M -28,576 -57%
LCM
154
Legato Capital Management
California
$1.26M +$1.24M +19,853 New
Nisa Investment Advisors
155
Nisa Investment Advisors
Missouri
$1.24M +$946K +15,180 +342%
CAPTRUST Financial Advisors
156
CAPTRUST Financial Advisors
North Carolina
$1.19M +$815K +13,075 +229%
WMSA
157
Weiss Multi-Strategy Advisers
New York
$1.18M -$122K -1,951 -9%
ProShare Advisors
158
ProShare Advisors
Maryland
$1.16M +$65.1K +1,044 +6%
GC
159
Guggenheim Capital
Illinois
$1.09M -$90.5K -1,453 -8%
B
160
Bailard
California
$1.07M +$87.2K +1,400 +9%
AQR Capital Management
161
AQR Capital Management
Connecticut
$1.02M +$168K +2,697 +20%
AWM
162
AE Wealth Management
Kansas
$1.02M +$1.01M +16,137 New
N
163
Natixis
France
$1.01M +$990K +15,881 New
NMG
164
New Millennium Group
Utah
$987K +$971K +15,587 New
Handelsbanken Fonder
165
Handelsbanken Fonder
Sweden
$975K +$224K +3,600 +31%
VAFP
166
Vahanian & Associates Financial Planning
New York
$964K -$57K -915 -6%
Los Angeles Capital Management
167
Los Angeles Capital Management
California
$949K +$85.2K +1,368 +10%
QPW
168
Quantum Private Wealth
Florida
$935K -$7.79K -125 -0.8%
JMPWA
169
JP Morgan Private Wealth Advisors
California
$935K -$65.9K -1,057 -7%
ACM
170
Aquatic Capital Management
Illinois
$924K +$143K +2,300 +19%
DnB Asset Management
171
DnB Asset Management
Norway
$904K +$259K +4,151 +41%
AIM
172
Aigen Investment Management
New York
$900K +$362K +5,810 +69%
AB
173
Amalgamated Bank
New York
$898K +$74K +1,187 +9%
JCIA
174
Jackson Creek Investment Advisors
Colorado
$895K +$881K +14,139 New
PMEF
175
Point72 Middle East FZE
United Arab Emirates
$878K +$864K +13,859 New
5 6
7
8 9

ITCI Hedge Fund Activity: Q2 2023 in Review

288 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2023, worth a combined $5.34B — up 18% from $4.55B a quarter earlier.

Buyers outnumbered sellers: 51 funds opened new ITCI positions and 36 closed out — a net gain of 15 holders — while 115 added to existing stakes and 78 trimmed.

The largest buyer was Lord, Abbett & Co, adding an estimated $36.7M. The largest seller was Wellington Management Group, cutting an estimated $207M.

  • 288 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2023, up from 274 in Q1 2023.
  • Funds reported $5.34B of Intra-Cellular Therapies Inc. stock for Q2 2023, up 18% quarter-over-quarter.
  • 51 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2023 and 36 closed out, a net change of +15 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q2 2023 was Lord, Abbett & Co, an estimated $36.7M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2023 was Wellington Management Group, an estimated $207M sold.

Based on aggregated 13F filings for Q2 2023.